Novartis Combo Extends Disease Control in Late-stage Trial for Rare Autoimmune Disorder

08:27 AM EST, 12/09/2025 (MT Newswires) -- Novartis (NOVN.SW) said Tuesday a late-stage trial showed that its ianalumab plus eltrombopag for primary immune thrombocytopenia was able to extend disease control by 45%, based on the primary endpoint of time to treatment failure. The pharmaceutical company added that the phase 3 Vayhit2 study highlighted "possible progress" for people with the rare, autoimmune disorder where the immune system destroys platelets. It added that the four once-monthly intravenous doses could reduce the need for chronic treatment and deliver durable disease control.